BRIMOCHOL PF
Asset
Fixed-dose combination of brimonidine and carbachol to induce pupil constriction for presbyopia.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Trial NCT06948357 is still running. Trial NCT06948357 updated in its registry on Apr 29, 2025. clinicaltrials.gov
Indications
1Presbyopia
Phase 2, Recruiting, NCT06948357, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors6
Every asset’s record: target, stage, trials and the evidence behind it.